[Source: TGen News] – Applied Biosystems, a division of Life Technologies Corporation (NASDAQ: LIFE), and the Translational Genomics Research Institute, today announced a strategic alliance designed to accelerate research into complex diseases and medical conditions. As part of this alliance, a team of scientists from TGen and Applied Biosystems will employ the SOLiD™ 3 System, Applied Biosystems’ next-generation genomic analysis platform, to sequence DNA from thousands of patients with a variety of diseases. The goal of this research is to translate scientific discoveries at the genetic level into knowledge about the underlying causes of disease that may ultimately be used to create cutting-edge tools for use in clinical diagnosis.
The alliance enables TGen researchers to apply best-of-breed sequencing technology across a broad spectrum of research efforts that focus on developing a more personalized approach to medicine. This approach, which is known as personalized medicine, represents a potential clinical shift from treatment of disease based on symptoms, to therapy that is specific to an individual’s unique genetic make up. Among the goals of this project is to advance the promise of personalized medicine by reducing the cost of genome sequencing to make it a routine diagnostic tool in medical care.
For more information click here.